Shanghai Fosun Pharmaceutical (SHA:600196) controlling subsidiary Xingsheng Xinhui received approval for drug clinical trials for XS-04 tablets.
XS-04 is used for the treatment of malignant tumors of the blood system, according to a Sept. 27 filing with the Shanghai bourse.
Shanghai Fosun Pharmaceutical has invested about 41.5 million yuan in research and development for XS-04 as of August.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments